We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial.
- Authors
Brown, Jacques P.; Prince, Richard L.; Deal, Chad; Recker, Robert R.; Kiel, Douglas P.; de Gregorio, Luiz H.; Hadji, Peyman; Hofbauer, Lorenz C.; Álvaro-Gracia, Jose M.; Huei Wang; Austin, Matthew; Wagman, Rachel B.; Newmark, Richard; Libanati, Cesar; San Martin, Javier; Bone, Henry G.
- Abstract
The article presents a randomized trial which compared the efficacy and safety of the monoclonal antibody denosumab with alendronate in postmenopausal women with low bone mass. Researchers found a greater reduction of bone turnover markers with denosumab treatment compared with alendronate therapy. Larger gains in bone mass density were found with denosumab. Both treatments had a similar safety profile.
- Subjects
CLINICAL trials; OSTEOPOROSIS; MONOCLONAL antibodies; DRUG efficacy; PHYSIOLOGY
- Publication
Journal of Bone & Mineral Research, 2009, Vol 24, Issue 1, p153
- ISSN
0884-0431
- Publication type
Article
- DOI
10.1359/jbmr.0809010